Karen W. Hoover
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Karen W. Hoover has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Weiming Zhu
Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA
3 shared publications- Samuel M. Jenness
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
2 shared publications Ya-Lin A. Huang
2 shared publications- Adrien Le Guillou
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA
1 shared publication - Andreea Creanga1 shared publication
- Arianne Folkema1 shared publication
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (11) , 1219-1230
Modeling the Potential Impact of Scaling Up Event-Driven PrEP Among Gay, Bisexual, and Other Men Who Have Sex With Men
Background: Event-driven preexposure prophylaxis (PrEP) (EDP), or PrEP taken around the time of sex, could be a preferred option over daily PrEP among cisgender gay, bisexual, and other men who have sex with men (MSM). However, recommendations for EDP versus daily dosing require consideration of optimal strategies for HIV prevention based on heterogeneous behavioral and biological PrEP indications. Methods: We used network-based mathematical HIV transmission modeling to understand the potential population-level impact of implementing EDP alongside daily PrEP using the 2-1-1 dosing schedule: 2 pills on the day of sex, 1 pill a day after, and 1 pill 2 days after. We simulated HIV transmission among 100,000 MSM in Atlanta, Georgia over 10 years. Compared with a baseline scenario with only daily PrEP and no EDP, we tested counterfactual scenarios that increased EDP use by changing initiation rates, expanding EDP to MSM not indicated for daily PrEP, and targeting EDP among MSM with low daily PrEP adherence who discontinued daily PrEP. Results: Increasing EDP initiation such that overall PrEP use was nearly double that at baseline (28.5% vs. 16.1%) yielded a percent of infections averted (PIA) of 18.3%. Expanding eligibility for EDP to any sexually active MSM resulted in a PIA of 15.8%. Targeting EDP for MSM discontinuing PrEP did not yield population-level improvements. Increasing initiation of EDP had a greater impact on PIA compared to improving EDP adherence. Conclusions: Using EDP to improve overall PrEP use resulted in reductions in HIV incidence, whereas targeted EDP initiation for MSM with low daily PrEP adherence did not improve outcomes over 10 years.
- 1 November 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 101 (11) , 1219-1230
Modeling the Potential Impact of Scaling Up Event-Driven PrEP Among Gay, Bisexual, and Other Men Who Have Sex With Men
Background: Event-driven preexposure prophylaxis (PrEP) (EDP), or PrEP taken around the time of sex, could be a preferred option over daily PrEP among cisgender gay, bisexual, and other men who have sex with men (MSM). However, recommendations for EDP versus daily dosing require consideration of optimal strategies for HIV prevention based on heterogeneous behavioral and biological PrEP indications. Methods: We used network-based mathematical HIV transmission modeling to understand the potential population-level impact of implementing EDP alongside daily PrEP using the 2-1-1 dosing schedule: 2 pills on the day of sex, 1 pill a day after, and 1 pill 2 days after. We simulated HIV transmission among 100,000 MSM in Atlanta, Georgia over 10 years. Compared with a baseline scenario with only daily PrEP and no EDP, we tested counterfactual scenarios that increased EDP use by changing initiation rates, expanding EDP to MSM not indicated for daily PrEP, and targeting EDP among MSM with low daily PrEP adherence who discontinued daily PrEP. Results: Increasing EDP initiation such that overall PrEP use was nearly double that at baseline (28.5% vs. 16.1%) yielded a percent of infections averted (PIA) of 18.3%. Expanding eligibility for EDP to any sexually active MSM resulted in a PIA of 15.8%. Targeting EDP for MSM discontinuing PrEP did not yield population-level improvements. Increasing initiation of EDP had a greater impact on PIA compared to improving EDP adherence. Conclusions: Using EDP to improve overall PrEP use resulted in reductions in HIV incidence, whereas targeted EDP initiation for MSM with low daily PrEP adherence did not improve outcomes over 10 years.
- 1 January 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (1) , 8-11
Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014─2022
Objectives: It is important to monitor national HIV preexposure prophylaxis (PrEP) use in the United States. However, PrEP use data in the Veterans Health Administration (VHA) system are not included in the current monitoring surveillance. To address this gap, we examined the trends in PrEP use among U.S. Veterans receiving health services in the VHA system. Methods: We analyzed 2014–2022 VHA data to identify the annual number and prevalence of persons aged ≥18 years prescribed PrEP, stratified by sex, age, race/ethnicity, and region. We also assessed trends by calculating the estimated annual percent change and 95% confidence intervals using Poisson models. Results: The number of Veterans prescribed PrEP increased from 361 in 2014 to 6050 in 2022 with an estimated annual percent change of 29.6% (95% CI: 22.6 to 37.1). Of 6050 Veterans with PrEP prescriptions in 2022, 95.2% were men, 4.8% were women, 50.4% were White, 24.5% Black or African American (Black), and 14.0% Hispanic or Latino. The prevalence of Black and Hispanic or Latino individuals prescribed PrEP increased significantly from 2014 to 2022. Conclusions: VHA data fill a gap in monitoring PrEP use in the United States. We observed an increasing trend in the number of Veterans prescribed PrEP similar to trends among persons with commercial or public health insurance.
- 1 January 2025
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 98 (1) , 8-11
Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014─2022
Objectives: It is important to monitor national HIV preexposure prophylaxis (PrEP) use in the United States. However, PrEP use data in the Veterans Health Administration (VHA) system are not included in the current monitoring surveillance. To address this gap, we examined the trends in PrEP use among U.S. Veterans receiving health services in the VHA system. Methods: We analyzed 2014–2022 VHA data to identify the annual number and prevalence of persons aged ≥18 years prescribed PrEP, stratified by sex, age, race/ethnicity, and region. We also assessed trends by calculating the estimated annual percent change and 95% confidence intervals using Poisson models. Results: The number of Veterans prescribed PrEP increased from 361 in 2014 to 6050 in 2022 with an estimated annual percent change of 29.6% (95% CI: 22.6 to 37.1). Of 6050 Veterans with PrEP prescriptions in 2022, 95.2% were men, 4.8% were women, 50.4% were White, 24.5% Black or African American (Black), and 14.0% Hispanic or Latino. The prevalence of Black and Hispanic or Latino individuals prescribed PrEP increased significantly from 2014 to 2022. Conclusions: VHA data fill a gap in monitoring PrEP use in the United States. We observed an increasing trend in the number of Veterans prescribed PrEP similar to trends among persons with commercial or public health insurance.
- Open Access
- 2 December 2022
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 71 (48) , 1505-1510
HIV Services and Outcomes During the COVID-19 Pandemic — United States, 2019–2021
This report describes HIV services and outcomes during the COVID-19 pandemic in the United States.
- 2 December 2022
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 71 (48) , 1505-1510
Open AccessHIV Services and Outcomes During the COVID-19 Pandemic — United States, 2019–2021
This report describes HIV services and outcomes during the COVID-19 pandemic in the United States.
- Open Access
Modeling an Integrated HIV Prevention and Care Continuum to Achieve the Ending the HIV Epidemic Goals
Objective: We sought to evaluate which combinations of HIV prevention and care activities would have the greatest impact towards reaching the US Ending the HIV Epidemic (EHE) plan goals of reducing HIV incidence at least 75% by 2025 and 90% by 2030. Design: A stochastic HIV transmission model for men who have sex with men (MSM), calibrated to local surveillance estimates in the Atlanta area, a focal EHE target jurisdiction. Methods: Model scenarios varied HIV screening rates relative to current levels, under different assumptions of how HIV-negative MSM would be linked to PrEP initiation, and also considered improvements to HIV care linkage and retention for those screening positive. Results: A 10-fold relative increase in HIV screening rates (to approximately biannual screening for black and Hispanic MSM and quarterly for white MSM) would lead to 43% of infections averted if integrated with PrEP initiation. Improvements to HIV care retention would avert 41% of infections if retention rates were improved 10-fold. If both screening and retention were jointly improved 10-fold, up to 74% of cumulative infections would be averted. Under this scenario, it would take 4 years to meet the 75% EHE goal and 12 years to meet the 90% goal for MSM in Atlanta. Conclusions: Interventions to improve HIV screening linked with PrEP for those screening negative, and HIV care retention would have a substantial impact on HIV prevention. However, additional interventions may be necessary to reach the EHE goal of a 90% reduction in incidence for Atlanta MSM by 2030.
Open AccessModeling an Integrated HIV Prevention and Care Continuum to Achieve the Ending the HIV Epidemic Goals
Objective: We sought to evaluate which combinations of HIV prevention and care activities would have the greatest impact towards reaching the US Ending the HIV Epidemic (EHE) plan goals of reducing HIV incidence at least 75% by 2025 and 90% by 2030. Design: A stochastic HIV transmission model for men who have sex with men (MSM), calibrated to local surveillance estimates in the Atlanta area, a focal EHE target jurisdiction. Methods: Model scenarios varied HIV screening rates relative to current levels, under different assumptions of how HIV-negative MSM would be linked to PrEP initiation, and also considered improvements to HIV care linkage and retention for those screening positive. Results: A 10-fold relative increase in HIV screening rates (to approximately biannual screening for black and Hispanic MSM and quarterly for white MSM) would lead to 43% of infections averted if integrated with PrEP initiation. Improvements to HIV care retention would avert 41% of infections if retention rates were improved 10-fold. If both screening and retention were jointly improved 10-fold, up to 74% of cumulative infections would be averted. Under this scenario, it would take 4 years to meet the 75% EHE goal and 12 years to meet the 90% goal for MSM in Atlanta. Conclusions: Interventions to improve HIV screening linked with PrEP for those screening negative, and HIV care retention would have a substantial impact on HIV prevention. However, additional interventions may be necessary to reach the EHE goal of a 90% reduction in incidence for Atlanta MSM by 2030.
- 6 September 2019
- Published by SAGE Publications in Journal of Women's Health
- Vol. 28 (9) , 1272-1285
Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review
Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective pill that HIV-negative individuals can take once daily to prevent HIV infection. Although PrEP is a private, user-controlled method that empowers women to protect themselves without relying on a partner's behavior, women's PrEP use has been extremely low. We systematically reviewed the literature to identify and summarize factors that may be affecting PrEP implementation for women in the United States. We conducted a search of the Centers for Disease Control and Prevention HIV/AIDS Prevention Research Synthesis Project database (MEDLINE, EMBASE, and CINAHL) and PubMed to identify peer-reviewed studies published between January 2000 and April 2018 that reported U.S. women's or health care providers' PrEP knowledge or awareness, willingness to use or prescribe, attitudes, barriers and facilitators to use or prescription, or PrEP adherence and discontinuation influences. Thirty-nine studies (26 women, 13 providers) met the eligibility criteria. In these studies, 0%–33% of women had heard of PrEP. Between 51% and 97% of women were willing to try PrEP, and 60%–92% of providers were willing to prescribe PrEP to women. Implementation barriers included access, cost, stigma, and medical distrust. Three studies addressed adherence or discontinuation. PrEP knowledge is low among women and providers. However, women and providers generally have positive views when aware of PrEP, including a willingness to use or prescribe PrEP to women. Most of the implementation barriers highlighted in studies were social or structural factors ( e.g ., access). Additional studies are needed to address research gaps, including studies of PrEP adherence and discontinuation.
- 6 September 2019
- Published by SAGE Publications in Journal of Women's Health
- Vol. 28 (9) , 1272-1285
Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review
Oral HIV pre-exposure prophylaxis (PrEP) is a highly effective pill that HIV-negative individuals can take once daily to prevent HIV infection. Although PrEP is a private, user-controlled method that empowers women to protect themselves without relying on a partner's behavior, women's PrEP use has been extremely low. We systematically reviewed the literature to identify and summarize factors that may be affecting PrEP implementation for women in the United States. We conducted a search of the Centers for Disease Control and Prevention HIV/AIDS Prevention Research Synthesis Project database (MEDLINE, EMBASE, and CINAHL) and PubMed to identify peer-reviewed studies published between January 2000 and April 2018 that reported U.S. women's or health care providers' PrEP knowledge or awareness, willingness to use or prescribe, attitudes, barriers and facilitators to use or prescription, or PrEP adherence and discontinuation influences. Thirty-nine studies (26 women, 13 providers) met the eligibility criteria. In these studies, 0%–33% of women had heard of PrEP. Between 51% and 97% of women were willing to try PrEP, and 60%–92% of providers were willing to prescribe PrEP to women. Implementation barriers included access, cost, stigma, and medical distrust. Three studies addressed adherence or discontinuation. PrEP knowledge is low among women and providers. However, women and providers generally have positive views when aware of PrEP, including a willingness to use or prescribe PrEP to women. Most of the implementation barriers highlighted in studies were social or structural factors ( e.g ., access). Additional studies are needed to address research gaps, including studies of PrEP adherence and discontinuation.
- 1 September 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 106, 11-12
Evaluation of a rapid point-of-care HIV screening program in an emergency department setting in Detroit, Michigan
- 1 September 2018
- Published by Elsevier in Journal of Clinical Virology
- Vol. 106, 11-12
Evaluation of a rapid point-of-care HIV screening program in an emergency department setting in Detroit, Michigan
- 15 July 2014
- Published by Springer Nature in Maternal and Child Health Journal
- Vol. 19 (4) , 733-738
Ectopic Pregnancy Among American Indian and Alaska Native Women, 2002–2009
To examine rates of ectopic pregnancy (EP) among American Indian and Alaska Native (AI/AN) women aged 15–44 years seeking care at Indian Health Service (IHS), Tribal, and urban Indian health facilities during 2002–2009. We used 2002–2009 inpatient and outpatient data from the IHS National Patient Information Reporting System to identify EP-associated visits and obtain the number of pregnancies among AI/AN women. Repeat visits for the same EP were determined by calculating the interval between visits; if more than 90 days between visits, the visit was considered related to a new EP. We identified 229,986 pregnancies among AI/AN women 15–44 years receiving care at IHS-affiliated facilities during 2002–2009. Of these, 2,406 (1.05 %) were coded as EPs, corresponding to an average annual rate of 10.5 per 1,000 pregnancies. The EP rate among AI/AN women was lowest in the 15–19 years age group (5.5 EPs per 1,000 pregnancies) and highest among 35–39 year olds (18.7 EPs per 1,000 pregnancies). EP rates varied by geographic region, ranging between 6.9 and 24.4 per 1,000 pregnancies in the Northern Plains East and the East region, respectively. The percentage of ectopic pregnancies found among AI/AN women is within the national 1–2 % range. We found relatively stable annual rates of EP among AI/AN women receiving care at IHS-affiliated facilities during 2002–2009, but considerable variation by age group and geographic region. Coupling timely diagnosis and management with public health interventions focused on tobacco use and sexually transmitted diseases may provide opportunities for reducing EP and EP-associated complications among AI/AN women.
- 15 July 2014
- Published by Springer Nature in Maternal and Child Health Journal
- Vol. 19 (4) , 733-738
Ectopic Pregnancy Among American Indian and Alaska Native Women, 2002–2009
To examine rates of ectopic pregnancy (EP) among American Indian and Alaska Native (AI/AN) women aged 15–44 years seeking care at Indian Health Service (IHS), Tribal, and urban Indian health facilities during 2002–2009. We used 2002–2009 inpatient and outpatient data from the IHS National Patient Information Reporting System to identify EP-associated visits and obtain the number of pregnancies among AI/AN women. Repeat visits for the same EP were determined by calculating the interval between visits; if more than 90 days between visits, the visit was considered related to a new EP. We identified 229,986 pregnancies among AI/AN women 15–44 years receiving care at IHS-affiliated facilities during 2002–2009. Of these, 2,406 (1.05 %) were coded as EPs, corresponding to an average annual rate of 10.5 per 1,000 pregnancies. The EP rate among AI/AN women was lowest in the 15–19 years age group (5.5 EPs per 1,000 pregnancies) and highest among 35–39 year olds (18.7 EPs per 1,000 pregnancies). EP rates varied by geographic region, ranging between 6.9 and 24.4 per 1,000 pregnancies in the Northern Plains East and the East region, respectively. The percentage of ectopic pregnancies found among AI/AN women is within the national 1–2 % range. We found relatively stable annual rates of EP among AI/AN women receiving care at IHS-affiliated facilities during 2002–2009, but considerable variation by age group and geographic region. Coupling timely diagnosis and management with public health interventions focused on tobacco use and sexually transmitted diseases may provide opportunities for reducing EP and EP-associated complications among AI/AN women.